Dr Reddys unveils generic version of Allegra D in US to treat common cold, flu
In a BSE filing, Dr Reddy's Labs(Dr Reddys) announced "launch of Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg extended-release tablets, USP, an over-the-counter (OTC) store-brand equivalent of Allegra-D 12 HR Allergy and Congestion extended-release tablets, in the United States market, as approved by the US Food and Drug Administration (USFDA)".
NEW DELHI: Drug major Dr Reddy's Laboratories Friday said it has launched generic Allegra-D, used to relieve symptoms caused by the common cold, flu or allergies, in the US market.
In a BSE filing, Dr Reddy's announced "launch of Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg extended-release tablets, USP, an over-the-counter (OTC) store-brand equivalent of Allegra-D 12 HR Allergy and Congestion extended-release tablets, in the United States market, as approved by the US Food and Drug Administration (USFDA)".
"We look forward to collaborating with our customers to provide high-quality, affordable alternatives to consumers," he added.
Quoting IRi data, Dr Reddy's Laboratories said Allegra-D 12 HR Allergy and Congestion extended-release tablets brand and generic had US sales of approximately USD 44 million for the most recent 12 months ending in May 2019.
Allegra-D 12 HR is a trademark of Aventisub II Inc.
Read Also: Dr Reddys launches OTC brand equivalent of Mucinex D ER tablets to treat phlegm
About Allegra-D
Allegra-D contains a combination of fexofenadine and pseudoephedrine. Fexofenadine is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Allegra-D is used to treat sneezing, runny or stuffy nose, itchy or watery eyes, hives, skin rash, itching, and other symptoms of allergies and the common cold. Allegra-D may also be used for purposes not listed in this medication guide.
Read Also: Dr Reddys plans to launch value-added drugs in US as part of diversification, market entry strategy
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd